-
EP4004013
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4004013
| EP4004013 - DINUCLEOTIDE COMPOUNDS FOR TREATING CANCERS AND MEDICAL USES THEREOF [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 26.01.2024 Database last updated on 19.07.2024 | |
| Former | Request for examination was made Status updated on 29.04.2022 | ||
| Former | The international publication has been made Status updated on 05.02.2021 | Most recent event Tooltip | 26.01.2024 | Withdrawal of application | published on 28.02.2024 [2024/09] | Applicant(s) | For all designated states Pinotbio, Inc. 803, 804, 805, 806, 807, 808, 813 156, Gwanggyo-ro Yeongtong-gu Suwon-si Gyeonggi-do 16506 / KR | [2022/22] | Inventor(s) | 01 /
JUNG, Doo-Young 201-1401, 281, Cheongsa-ro, Seo-gu Daejeon 35205 / KR | 02 /
LEE, Jin-Soo 303-1903, 126, Seongbok 2-ro, Suji-gu Yongin-si, Gyeonggi-do 16851 / KR | 03 /
CHO, Hyun-Yong 105-1602, 4-27, Yeongtong-ro 90beon-gil, Yeongtong-gu Suwon-si, Gyeonggi-do 16692 / KR | [2022/22] | Representative(s) | Graf von Stosch Patentanwaltsgesellschaft mbH Prinzregentenstraße 22 80538 München / DE | [2022/22] | Application number, filing date | 20847547.5 | 29.07.2020 | [2022/22] | WO2020KR10006 | Priority number, date | KR20190092688 | 30.07.2019 Original published format: KR 20190092688 | [2022/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021020879 | Date: | 04.02.2021 | Language: | EN | [2021/05] | Type: | A1 Application with search report | No.: | EP4004013 | Date: | 01.06.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.02.2021 takes the place of the publication of the European patent application. | [2022/22] | Search report(s) | International search report - published on: | KR | 04.02.2021 | (Supplementary) European search report - dispatched on: | EP | 10.07.2023 | Classification | IPC: | C07H19/10, C07H19/207, C07H21/04, C07H1/00, A61P35/00, A61K31/7084 | [2023/32] | CPC: |
C07H19/207 (EP);
C07H19/10 (EP,KR);
C07H21/04 (EP,US);
A61K31/7042 (KR);
A61P35/00 (EP,KR,US);
C07H1/00 (EP)
|
| Former IPC [2022/22] | C07H19/24, C07H19/073, C07H1/00, A61K31/7042, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/22] | Title | German: | DINUKLEOTID-VERBINDUNGEN ZUR BEHANDLUNG VON KREBS UND IHRE MEDIZINISCHEN VERWENDUNGEN | [2022/22] | English: | DINUCLEOTIDE COMPOUNDS FOR TREATING CANCERS AND MEDICAL USES THEREOF | [2022/22] | French: | COMPOSÉS DINUCLÉOTIDIQUES POUR LE TRAITEMENT DE CANCERS ET LEURS UTILISATIONS MÉDICALES | [2022/22] | Entry into regional phase | 01.02.2022 | National basic fee paid | 01.02.2022 | Search fee paid | 01.02.2022 | Designation fee(s) paid | 01.02.2022 | Examination fee paid | Examination procedure | 01.02.2022 | Examination requested [2022/22] | 25.01.2024 | Application withdrawn by applicant [2024/09] | Fees paid | Renewal fee | 28.07.2022 | Renewal fee patent year 03 | 10.07.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [YA]EP0841344 (YAMASA CORP [JP]) [Y] 1-9 * abstract * [A] 10-16; | [YA]EP3214090 (FUJIFILM CORP [JP]) [Y] 1-9 * abstract * * claim - *[A] 10-16; | [YA] - SHINJI MIURA ET AL, "Comparison of 1-(2-deoxy-2-fluoro-4-thio-b-d- arabinofuranosyl)cytosine with gemcitabine in its antitumor activity", CANCER LETTERS, (19990101), vol. 144, doi:10.1016/S0304-3835(99)00221-9, pages 177 - 182, XP055213437 [Y] 1-9 * abstract * * page 181, paragraph last * [A] 10-16 DOI: http://dx.doi.org/10.1016/S0304-3835(99)00221-9 | International search | [YX]WO9711087 (LIPITEK INTERNATIONAL INC [US], et al) [Y] 10-16 [X] 1-6; | [YX]US2010151001 (SCHOTT HERBERT [DE], et al) [Y] 10-16 [X] 1-6; | [Y] - SUGIYAMA, H. et al., "Specific detection of C-4`hydroxylated abasic sites generated by bleomycin and neocarzinostatin in DNA", J. am. chem. soc., 1990, Vol. 112, No. 13, pp. 5252-5257 abstract; scheme II, XP055776379 [Y] 10-16 | [YX] - Schott, H. ; Schott, S. ; Schwendener, R.A., "Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding", Bioorganic & medicinal chemistry, Elsevier, NL, NL, (20091001), vol. 17, no. 19, doi:10.1016/j.bmc.2009.08.033, ISSN 0968-0896, pages 6824 - 6831, XP026601529 [Y] 10-16 [X] 1-6 DOI: http://dx.doi.org/10.1016/j.bmc.2009.08.033 | [YX] - Strasser, S. ; Maier, S. ; Leisser, C. ; Saiko, P. ; Madlener, S. ; Bader, Y. ; Bernhaus, A. ; Gueorguieva, M. ; Richter, S. ; Mader, R.M. ; Wesierska-Gadek, J. ; Schott, H. ; Szekeres, T. ; Fritzer-Szekeres, M. ; Krupitza, G., "5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2", DIFFERENTIATION., SPRINGER VERLAG., DE, DE, (20061201), vol. 74, no. 9-10, doi:10.1111/j.1432-0436.2006.00082.x, ISSN 0301-4681, pages 488 - 498, XP026770200 [Y] 10-16 [X] 1-6 DOI: http://dx.doi.org/10.1111/j.1432-0436.2006.00082.x |